How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Nanotechnology has quietly progressed through three distinct generations, and the third is now reshaping how deep-tech R&D ...

As inference workloads evolve from discrete question-and-answer exchanges into persistent, multi-step agentic systems, GPU ...

Shanku Niyogi of Databricks walks through the architecture behind Lakebase, LTAP and Lakehouse//RT – and renames an industry ...

A decision tree regression system incorporates a set of if-then rules to predict a single numeric value. Decision tree regression is rarely used by itself because it overfits the training data, and so ...

Welcome everybody to Recursion's Earnings Call. I'm Chris Gibson, Co-Founder and CEO, and I'm excited to take you through Recursions 2024, 2025 and the time ahead. So with that we'll jump into the ...

Recursion Pharmaceuticals has agreed to acquire the Oxford, U.K.-based artificial intelligence (AI) drug pioneer Exscientia, the companies said today, in a deal that consolidates two leaders in ...

Ask the publishers to restore access to 500,000+ books. An icon used to represent a menu that can be toggled by interacting with this icon. A line drawing of the Internet Archive headquarters building ...

I originally created this as a short to-do list of study topics for becoming a software engineer, but it grew to the large list you see today. After going through this study plan, I got hired as a ...